Alnylam Pharmaceuticals, Inc.
Every calculator, already run for ALNY
Open the full toolkit →You have the numbers on ALNY. Get the argument.
A written report on which of these readings actually decide the outcome for Alnylam Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
29 analysts covering ALNYAnalyst Price Target Disagreement for Alnylam Pharmaceuticals, Inc.
Wall Street's bull case implies +110% from the current price; the bear case implies +0%. A 110% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ALNY
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for…
ALNY — frequently asked
Is ALNY a buy right now?
Wall Street's consensus rating on Alnylam Pharmaceuticals, Inc. is Buy across 29 analysts, with a mean price target of $371.35 (+45% vs. the current $255.36). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ALNY overvalued?
ALNY trades at 44.6x trailing earnings, against a DCF fair value of $79 per share. The current price implies 20% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ALNY's next earnings date?
Alnylam Pharmaceuticals, Inc. is next scheduled to report earnings around Oct 29, 2026. A full ALNY research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Alnylam Pharmaceuticals, Inc.?
Analysts covering Alnylam Pharmaceuticals, Inc. (ALNY) range from a bear-case target of $256.00 to a bull-case high of $536.00, with a mean consensus target of $371.35 across 26 analysts. The spread of $280.00 (110% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Alnylam Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Alnylam Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ALNY research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Alnylam Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.